相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Ralf Reilmann et al.
LANCET NEUROLOGY (2019)
Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor
Daniel Ryskamp et al.
NEUROBIOLOGY OF DISEASE (2019)
Brain structure in juvenile-onset Huntington disease
Alexander Tereshchenko et al.
NEUROLOGY (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model
Freja K. Ekman et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease
Marta Garcia-Miralles et al.
MOLECULAR NEUROBIOLOGY (2019)
The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy
Heidemarie Kletzl et al.
NEUROMUSCULAR DISORDERS (2019)
Combination of stem cell and gene therapy ameliorates symptoms in Huntington's disease mice
In Ki Cho et al.
NPJ REGENERATIVE MEDICINE (2019)
Huntington's disease: a clinical review
P. McColgan et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic
Jana Miniarikova et al.
MOLECULAR THERAPY (2018)
Mechanism of neuroprotection by trehalose: controversy surrounding autophagy induction
He-Jin Lee et al.
CELL DEATH & DISEASE (2018)
Effect of Trinucleotide Repeats in the Huntington's Gene on Intelligence
Jessica K. Lee et al.
EBIOMEDICINE (2018)
Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease
Dagmar E. Ehrnhoefer et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis
Caterina Fusilli et al.
LANCET NEUROLOGY (2018)
Therapeutic approaches to Huntington disease: from the bench to the clinic
Nicholas S. Caron et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease
Susanna Waters et al.
JOURNAL OF HUNTINGTONS DISEASE (2018)
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease
Emma M. Coppen et al.
DRUGS (2017)
Huntington's Disease: Relationship Between Phenotype and Genotype
Yi-Min Sun et al.
MOLECULAR NEUROBIOLOGY (2017)
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Andrew McGarry et al.
NEUROLOGY (2017)
MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain
L. Samaranch et al.
GENE THERAPY (2017)
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease
Su Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study
Davina J. Hensman Moss et al.
LANCET NEUROLOGY (2017)
Therapies targeting DNA and RNA in Huntington's disease (vol 16, pg 837, 2017)
E. J. Wild et al.
LANCET NEUROLOGY (2017)
CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo
Alex Mas Monteys et al.
MOLECULAR THERAPY (2017)
Substance abuse may hasten motor onset of Huntington disease Evaluating the Enroll-HD database
Jordan L. Schultz et al.
NEUROLOGY (2017)
The CREST-E study of creatine for Huntington disease A randomized controlled trial
Steven M. Hersch et al.
NEUROLOGY (2017)
Risk factors for the onset and progression of Huntington disease
Ting-Kuang Chao et al.
NEUROTOXICOLOGY (2017)
RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA
Sebastian Aguiar et al.
TRANSLATIONAL NEURODEGENERATION (2017)
A survey-based study identifies common but unrecognized symptoms in a large series of juvenile Huntington's disease
Amelia D. Moser et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2017)
Therapies targeting DNA and RNA in Huntington's disease
Edward J. Wild et al.
LANCET NEUROLOGY (2017)
Modern Genome Editing Technologies in Huntington's Disease Research
Tuyana B. Malankhanova et al.
JOURNAL OF HUNTINGTONS DISEASE (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons
Dagmar E. Ehrnhoefer et al.
EXPERIMENTAL NEUROLOGY (2016)
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
Michal Geva et al.
HUMAN MOLECULAR GENETICS (2016)
Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
Stanley T. Crooke et al.
MOLECULAR THERAPY (2016)
The P42 peptide and Peptide-based therapies for Huntington's disease
Cecilia Marelli et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
Suzan M. Hammond et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
Marta Garcia-Miralles et al.
SCIENTIFIC REPORTS (2016)
Revisiting the Lamotrigine-Mediated Effect on Hippocampal GABAergic Transmission
Yu-Yin Huang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
MIND diet associated with reduced incidence of Alzheimer's disease
Martha Clare Morris et al.
ALZHEIMERS & DEMENTIA (2015)
An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease
Sigurd D. Suessmuth et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Huntington's disease: An update of therapeutic strategies
Ashok Kumar et al.
GENE (2015)
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
Ferdinando Squitieri et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
A Randomized, Placebo-Controlled Trial of AFQ056 for the Treatment of Chorea in Huntington's Disease
Ralf Reilmann et al.
MOVEMENT DISORDERS (2015)
Ethyl-Eicosapentaenoic Acid Treatment in Huntington's Disease: A Placebo-Controlled Clinical Trial
Joaquim J. Ferreira et al.
MOVEMENT DISORDERS (2015)
Therapeutic genome editing: prospects and challenges
David Benjamin Turitz Cox et al.
NATURE MEDICINE (2015)
Triheptanoin improves brain energy metabolism in patients with Huntington disease
Isaac Mawusi Adanyeguh et al.
NEUROLOGY (2015)
Riluzole Stimulates BDNF Release from Human Platelets
Patrick Tuerck et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Huntington disease
Gillian P. Bates et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease
Gelareh Mazarei et al.
JOURNAL OF HUNTINGTONS DISEASE (2015)
An update on Huntington's disease: from the gene to the clinic
Samuel D. Kim et al.
CURRENT OPINION IN NEUROLOGY (2014)
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
HUMAN GENE THERAPY (2014)
SAFETY AND TOLERABILITY OF SELISISTAT FOR THE TREATMENT OF HUNTINGTON'S DISEASE: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL
R. Reilmann et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Multisource Ascertainment of Huntington Disease in Canada: Prevalence and Population at Risk
Emily R. Fisher et al.
MOVEMENT DISORDERS (2014)
Huntington disease: natural history, biomarkers and prospects for therapeutics
Christopher A. Ross et al.
NATURE REVIEWS NEUROLOGY (2014)
Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice
Alejandro Dau et al.
NEUROBIOLOGY OF DISEASE (2014)
PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Herminia D. Rosas et al.
NEUROLOGY (2014)
Ubiquilin-1 Overexpression Increases the Lifespan and Delays Accumulation of Huntingtin Aggregates in the R6/2 Mouse Model of Huntington's Disease
Nathaniel Safren et al.
PLOS ONE (2014)
Trehalose Reverses Cell Malfunction in Fibroblasts from Normal and Huntington's Disease Patients Caused by Proteosome Inhibition
Maria Angeles Fernandez-Estevez et al.
PLOS ONE (2014)
Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington's Disease
Liliana B. Menalled et al.
PLOS ONE (2014)
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Nikolai A. Naryshkin et al.
SCIENCE (2014)
Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease
William M. Pryor et al.
SCIENCE SIGNALING (2014)
Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records
Stephen J. W. Evans et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease
Karl Kieburtz et al.
MOVEMENT DISORDERS (2013)
Epigenetic Mechanisms of Neurodegeneration in Huntington's Disease
Junghee Lee et al.
NEUROTHERAPEUTICS (2013)
Huntington's disease: underlying molecular mechanisms and emerging concepts
John Labbadia et al.
TRENDS IN BIOCHEMICAL SCIENCES (2013)
Relationship of Mediterranean Diet and Caloric Intake to Phenoconversion in Huntington Disease
Karen Marder et al.
JAMA NEUROLOGY (2013)
A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease
Karl Kieburtz et al.
JAMA NEUROLOGY (2013)
An Independent Study of the Preclinical Efficacy of C2-8 in the R6/2 Transgenic Mouse Model of Huntington's Disease
Nan Wang et al.
JOURNAL OF HUNTINGTONS DISEASE (2013)
Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
JOURNAL OF HUNTINGTONS DISEASE (2013)
Striatal Volume Contributes to the Prediction of Onset of Huntington Disease in Incident Cases
Elizabeth H. Aylward et al.
BIOLOGICAL PSYCHIATRY (2012)
Substance abuse may be a risk factor for earlier onset of Huntington disease
Joanne A. Byars et al.
JOURNAL OF NEUROLOGY (2012)
Measures of growth in children at risk for Huntington disease
Jessica K. Lee et al.
NEUROLOGY (2012)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice
Mireia Garriga-Canut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Subunit order of eukaryotic TRiC/CCT chaperonin by cross-linking, mass spectrometry, and combinatorial homology modeling
Nir Kalisman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Meclizine is neuroprotective in models of Huntington's disease
Vishal M. Gohil et al.
HUMAN MOLECULAR GENETICS (2011)
Oligonucleotide therapeutic approaches for Huntington disease
Dinah W. Y. Sah et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
Justo Garcia de Yebenes et al.
LANCET NEUROLOGY (2011)
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene/Allele-Specific Silencing of Mutant Huntingtin
Jeffrey B. Carroll et al.
MOLECULAR THERAPY (2011)
Management of Huntington's disease: role of tetrabenazine
Marina de Tommaso et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2011)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease
Karl Kieburtz et al.
ARCHIVES OF NEUROLOGY (2010)
Tetrabenazine is neuroprotective in Huntington's disease mice
Hongyu Wang et al.
MOLECULAR NEURODEGENERATION (2010)
Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice
Austen J. Milnerwood et al.
NEURON (2010)
Sustained Effects of Nonallele-Specific Huntingtin Silencing
Valerie Drouet et al.
ANNALS OF NEUROLOGY (2009)
Allele-Selective Inhibition of Mutant Huntingtin by Peptide Nucleic Acid-Peptide Conjugates, Locked Nucleic Acid, and Small Interfering RNA
Jiaxin Hu et al.
OLIGONUCLEOTIDE THERAPEUTICS (2009)
Combination therapy with Coenzyme Q(10) and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's Diseases
Lichuan Yang et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease
Amber L. Southwell et al.
JOURNAL OF NEUROSCIENCE (2009)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin
Shu-ichi Okamoto et al.
NATURE MEDICINE (2009)
Randomized Controlled Trial of Ethyl-Eicosapentaenoic Acid in Huntington Disease
ARCHIVES OF NEUROLOGY (2008)
AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease
Nicholas R. Franich et al.
MOLECULAR THERAPY (2008)
The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice
Elizabeth A. Thomas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Lamotrigine in motor and mood symptoms of Huntington's disease
Yu-Chih Shen
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2008)
Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment
Flaviano Giorgini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Glutamate uptake is reduced in prefrontal cortex in Huntington's disease
Bjornar Hassel et al.
NEUROCHEMICAL RESEARCH (2008)
A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse
Vanita Chopra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Sodium phenylbutyrate in Huntington's disease: A dose-finding study
Penelope Hogarth et al.
MOVEMENT DISORDERS (2007)
Riluzole in Huntington's disease: A 3-year, randomized controlled study
G. Bernhard Landwehrmeyer et al.
ANNALS OF NEUROLOGY (2007)
Modulation of nucleosome dynamics in Huntington's disease
Edward C. Stack et al.
HUMAN MOLECULAR GENETICS (2007)
Pharmacological properties of BN82451: A novel multitargeting neuroprotective agent
Pierre Etienne Chabrier et al.
CNS DRUG REVIEWS (2007)
Congo red and protein aggregation in neurodegenerative diseases
Petrea Frid et al.
BRAIN RESEARCH REVIEWS (2007)
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease
Hoon Ryu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease
Soon-Tae Lee et al.
BRAIN RESEARCH (2006)
Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease
Lindsay R. Pattison et al.
JOURNAL OF NEUROLOGY (2006)
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin
Rona K. Graham et al.
CELL (2006)
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase
M Borrell-Pagès et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells
ZK Mao et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin
H Wang et al.
HUMAN MOLECULAR GENETICS (2006)
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
SM Hersch et al.
NEUROLOGY (2006)
The therapeutic role of creatine in Huntington's disease
H Ryu et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Ethyl-EPA in Huntington disease - A double-blind, randomized, placebo-controlled trial
BK Puri et al.
NEUROLOGY (2005)
Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease
JR Pineda et al.
JOURNAL OF NEUROCHEMISTRY (2005)
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model
SQ Harper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Amantadine inhibits NMDA receptors by accelerating channel closure during channel block
TA Blanpied et al.
JOURNAL OF NEUROSCIENCE (2005)
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease
G Gardian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease
M Tanaka et al.
NATURE MEDICINE (2004)
Neuroprotection in Huntingtons disease:: a 2-year study on minocycline
RM Bonelli et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2004)
Minocycline in Huntington's disease: A pilot study
M Thomas et al.
MOVEMENT DISORDERS (2004)
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
B Ravikumar et al.
NATURE GENETICS (2004)
Creatine supplementation in Huntington's disease - A placebo-controlled pilot trial
P Verbessem et al.
NEUROLOGY (2003)
Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease
P Klivenyi et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
E Hockly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Glutamine and glutamate as vital metabolites
P Newsholme et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2003)
Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders
I Sánchez et al.
NATURE (2003)
Lamotrigine - A review of its use in bipolar disorder
DR Goldsmith et al.
DRUGS (2003)
Apoptotic changes in the aged brain are triggered by interleukin-1β-induced activation of p38 and reversed by treatment with eicosapentaenoic acid
DSD Martin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic model of Huntington's disease
CD Keene et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to γ-irradiation
PE Lonergan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The biochemistry of n-3 polyunsaturated fatty acids
DB Jump
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Therapeutic effects of coenzyme Q(10) and remacemide in transgenic mouse models of Huntington's disease
RJ Ferrante et al.
JOURNAL OF NEUROSCIENCE (2002)
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
M Chen et al.
NATURE MEDICINE (2000)
Amyloid-like inclusions in Huntington's disease
DP McGowan et al.
NEUROSCIENCE (2000)
分享论文
